Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.70 |
| ▸ | GSK3B | P49841 | 1/20 | 0.70 |
| ▸ | PRKDC | P78527 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2483511 | 0.88 | ATR (0.76) | ATRGSK3BPRKDC | |
| SCHEMBL2512070 | 0.85 | ATR (0.80) | ATRGSK3BPRKDC | |
| SCHEMBL13138263 | 0.82 | ATR (0.74) | ATRGSK3BPRKDC | |
| SCHEMBL2513058 | 0.82 | ATR (1.00) | ATRGSK3BPRKDC | |
| SCHEMBL2524168 | 0.82 | ATR (0.68) | ATRGSK3BPRKDC | |
| SCHEMBL13137928 | 0.81 | ATR (1.00) | ATRGSK3BPRKDC | |
| SCHEMBL24248235 | 0.79 | ATR (0.85) | ATRGSK3BPRKDC | |
| SCHEMBL13137874 | 0.78 | ATR (0.65) | ATRGSK3BPRKDC | |
| SCHEMBL16489083 | 0.78 | ATR (0.62) | ATRGSK3BPRKDC | |
| SCHEMBL20283867 | 0.78 | ATR (0.84) | ATRGSK3BPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479784-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190047995-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047995-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885GSK3B 216/4885PRKDC 23/4885 |
| US-10479784-B2 | Substituted pyrazin-2-amines as inhibitors of ATR kinase | ATR, CHEK2, CHEK1 | ATR 1/4885GSK3B 313/4885PRKDC 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.